Tobacco Dependence
Conditions
Keywords
Smoking Cessation, Tobacco Use Disorder
Brief summary
This study is to see if a new nicotine replacement therapy safely helps people to quit smoking if it is used the way it would be if it were sold at the pharmacy and used at home. Approximately 1500 subjects will be enrolled into the study. The study will require participants to use the treatment for 12 weeks and there will be a 14-week follow-up period. The study will be conducted in approximately 20 pharmacies across the United States. At the first visit to the pharmacy, participants will be asked some questions to see if they are eligible to participate. Participants will be asked to sign a consent form if they agree to participate. Participants will answer some more questions, and blow into a machine to measure their carbon monoxide (CO) levels to make sure they qualify for the trial. Participants will be asked to go to a nearby dentist who will look at their mouths. Participants will go back to the pharmacy and if they qualify, they will be given a supply of their assigned treatment. They will have an equal chance of receiving a treatment that has a drug in it or one that has no drug in it. They will be given a diary to keep track of how much of the treatment they use. Subjects will go to the pharmacy four more times to hand in their diaries and blow into a machine that will measure their CO levels. At the last visit, subjects will have their mouths examined by a dentist again to have their mouth checked. Subjects will receive four telephone calls during the study where they will be asked some questions. After the 12 week treatment period, subjects will receive two to three more telephone calls, where they will be asked to answer some questions. Participants may be asked to come back to the pharmacy two more times to blow into the carbon monoxide machine again.
Detailed description
This trial is a multi-center, randomized, double blind, placebo-controlled parallel group study to measure the efficacy and safety of a new nicotine replacement therapy for smoking cessation in a naturalistic environment. Subjects will be randomized in a 2:1 ratio (active to placebo). It is anticipated that data from about 450 in the active treatment group at Week 12 will be required for the safety analysis. In order to obtain that number of subjects, approximately 1500 subjects will need to be enrolled into the Use phase of the study, 1000 in the active arm and 500 in the placebo arm. Based on the directions for use on the Drug Facts label, the study will include six weeks of full study drug treatment and then six weeks of progressive tapering drug treatment (Weeks 1-12). There will be a 14-week post-use follow up period. This trial will be conducted in three sequential phases: Enrollment (baseline), Use and Post-use Follow-up. The Enrollment Phase will be conducted in approximately 20 pharmacies in nine diverse geographical areas in the continental United States. Subjects who qualify to participate in the study will be given three units of investigational product, a subject diary for tracking investigational product use and a medical problems worksheet to assist in the collection of AE information. Subjects will also be given a small hand counter and will be encouraged to use it to help keep track of the number of doses they use each day. Subjects will also be given a card with contact information for the pharmacy and study nurses. Where needed, the subject can also speak with the study physician. During the Use Phase, the collection of data related to efficacy will be accomplished during four return visits to the pharmacy (at weeks 2, 4, 6 and 12). Self-reported abstinence will be verified by carbon monoxide (CO) measurements obtained at each pharmacy visit. Subjects will be given a subject use diary at each follow-up and re-supply visit and completed diaries will be collected each time the subject returns to the pharmacy. Subjects can return to the pharmacy for additional supplies at any time during their participation. Empty units will be returned during these visits. Safety data will be collected during four telephone interviews, conducted by trained nurse interviewers, at weeks 2, 4, 6 and 12. If a subject reports an adverse event during a visit (return visit or resupply visit), this information will be immediately forwarded to the nurse interviewers for follow-up. Subjects may also initiate a call to the study nurses themselves to discuss health problems. All AE information collected will be reviewed by a physician as the adverse events are collected. A standardized visual mouth examination will be conducted by trained dentists at the enrollment visit and at the Week 12 return visit. During the Post-use Follow-up period, self-reported efficacy and safety data will be collected during two telephone interviews initiated by trained nurse interviewers (at weeks 16 and 26). Subjects reporting abstinence since the last visit or abstinence for the prior seven days during these two interviews will be asked to return to the pharmacy to verify abstinence with an exhaled CO measurement. An additional telephone interview will be conducted between Week-12 and Week-16, by trained nurse interviewers, who will administer the End of Treatment questions to those subjects who have reported the following product use behavior that are inconsistent with the directions on the Drug Facts label: Use of more than 64 doses in a 24-hour period at least one time or use of more than 4 doses per hour at least one time based on the diary or their self report.
Interventions
DRUGPlacebo
Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
DRUGNicotine
Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks
Sponsors
McNeil AB
GlaxoSmithKline
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must be males or females 18 years of age or older who currently smoke cigarettes and are willing to stop smoking
Exclusion criteria
* Subjects must not have a recent history of unstable angina, myocardial infarction or stroke * They must not have a suspected malignant and/or erosive oral lesion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Continuous Smoking Abstinence | through Week 6 | Number of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking from Week 2 through Week 6. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Continuous Smoking Abstinence | through Week 26 | Number of participants with carbon monoxide (CO)-verified self report of continuous abstinence from smoking from Week 2 to Weeks 4, 6, 12, 16, and 26. |
| Number of Participants With 7-day Point Prevalence Abstinence | through Week 26 | Number of participants with carbon monoxide (CO)-verified self-reported 7-day point prevalence abstinence from smoking at Weeks 2, 4, 6, 12, 16, and 26. |
| Mean Number of Daily Doses | Week 1 | Mean number of daily doses by study week. |
| Percentage of Participants With High Dosage | within 12 Weeks | Percentage of participants who used more than 64 doses in any one-day period. |
| Percentage of Participants With High Usage | within 12 Weeks | Percentage of participants who used more than four doses in any one-hour period. |
| Highest Rating of Desire/Urge to Smoke on a Categorical Scale | within 12 Weeks | Participants are asked if during the last 24 hours they experienced the Desire/Urge to Smoke on a 5-grade categorical scale from Not at all to Extremely so. |
| Highest Rating of Irritability/Frustration/Anger on a Categorical Scale | within 12 Weeks | Participants are asked if during the last 24 hours they experienced Irritability/Frustration/Anger on a 5-grade categorical scale from Not at all to Extremely so. |
| Highest Rating of Restlessness on a Categorical Scale | within 12 Weeks | Participants are asked if during the last 24 hours they experienced Restlessness on a 5-grade categorical scale from Not at all to Extremely so. |
| Participant Score for General Perception of the Product | through Week 12 | Participants are asked to rate their general perception of the investigational product on a scale of 1-10, where 1=very poor and 10=excellent. |
| Highest Rating of Anxiety on a Categorical Scale | within 12 Weeks | Participants are asked if during the last 24 hours they experienced Anxiety on a 5-grade categorical scale from Not at all to Extremely so. |
| Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale | within 12 Weeks | Participants are asked if during the last 24 hours they experienced Dysphoric or Depressed Mood on a 5-grade categorical scale from Not at all to Extremely so. |
| Highest Rating of Insomnia on a Categorical Scale | within 12 Weeks | Participants are asked if during the last 24 hours they experienced Insomnia on a 5-grade categorical scale from Not at all to Extremely so. |
| Highest Rating of Increased Appetite on a Categorical Scale | within 12 Weeks | Participants are asked if during the last 24 hours they experienced Increased Appetite on a 5-grade categorical scale from Not at all to Extremely so. |
| Participant Score for Product Effectiveness in Dealing With Cravings | through 12 Weeks | Participants are asked to rate the product in its effectiveness for dealing with cravings, on a scale of 1-5, where 1=not at all effective, and 5=extremely effective. |
| Participant Score for Speed of Action | through 12 Weeks | Participants are asked to rate the product for speed of action, on a scale of 1-9, where 1=extremely slow and 9=extremely fast. |
| Participant Score for Change in Perception | through 12 Weeks | Participants are asked to rate how their opinion has changed since the first time they used it, on a score of 1-5, where 1=I like it much less now and 5=I like it much more now. |
| Participant Score for Product Convenience | through 12 Weeks | Participants are asked to rate how convenient the product is to use, on a scale of 1-5, where 1=not at all convenient and 5=extremely convenient. |
| Highest Rating of Difficulty Concentrating on a Categorical Scale | within 12 Weeks | Participants are asked if during the last 24 hours they experienced Difficulty Concentrating on a 5-grade categorical scale from Not at all to Extremely so. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo 0 mg Oral NRT, up to 4 times per hour for 12 weeks | 244 |
| Nicotine 1 mg Oral NRT, up to 4 times per hour for 12 weeks | 13 |
| Total | 257 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 1 | 0 |
| Overall Study | Death | 1 | 0 |
| Overall Study | Difficulty Contacting Subject | 2 | 0 |
| Overall Study | Lost to Follow-up | 19 | 1 |
| Overall Study | Study Terminated by Sponsor | 209 | 12 |
| Overall Study | Withdrawal by Subject | 12 | 0 |
Baseline characteristics
| Characteristic | Placebo | Nicotine | Total |
|---|---|---|---|
| Age Continuous | 47.1 years STANDARD_DEVIATION 14 | 49.9 years STANDARD_DEVIATION 11.4 | 47.2 years STANDARD_DEVIATION 13.9 |
| Region of Enrollment United States | 244 participants | 13 participants | 257 participants |
| Sex: Female, Male Female | 131 Participants | 8 Participants | 139 Participants |
| Sex: Female, Male Male | 113 Participants | 5 Participants | 118 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 33 / 242 | 8 / 13 |
| serious Total, serious adverse events | 4 / 242 | 1 / 13 |
Outcome results
Primary
Number of Participants With Continuous Smoking Abstinence
Number of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking from Week 2 through Week 6.
Time frame: through Week 6
Population: The study was terminated prematurely due to a technical issue (randomization error) and no data are available.
Secondary
Highest Rating of Anxiety on a Categorical Scale
Participants are asked if during the last 24 hours they experienced Anxiety on a 5-grade categorical scale from Not at all to Extremely so.
Time frame: within 12 Weeks
Population: Analysis was limited to participants who used study medication at least once and who completed the questionnaire.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Highest Rating of Anxiety on a Categorical Scale | Somewhat | 23.9 Percentage of Participants |
| Placebo | Highest Rating of Anxiety on a Categorical Scale | Very much so | 13.0 Percentage of Participants |
| Placebo | Highest Rating of Anxiety on a Categorical Scale | Moderately so | 15.2 Percentage of Participants |
| Placebo | Highest Rating of Anxiety on a Categorical Scale | Extremely so | 3.3 Percentage of Participants |
| Placebo | Highest Rating of Anxiety on a Categorical Scale | Not at all | 44.6 Percentage of Participants |
| Nicotine | Highest Rating of Anxiety on a Categorical Scale | Extremely so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Anxiety on a Categorical Scale | Not at all | 50.0 Percentage of Participants |
| Nicotine | Highest Rating of Anxiety on a Categorical Scale | Somewhat | 0 Percentage of Participants |
| Nicotine | Highest Rating of Anxiety on a Categorical Scale | Moderately so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Anxiety on a Categorical Scale | Very much so | 50.0 Percentage of Participants |
Secondary
Highest Rating of Desire/Urge to Smoke on a Categorical Scale
Participants are asked if during the last 24 hours they experienced the Desire/Urge to Smoke on a 5-grade categorical scale from Not at all to Extremely so.
Time frame: within 12 Weeks
Population: Analysis was limited to participants who used study medication at least once and who completed the questionnaire.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Highest Rating of Desire/Urge to Smoke on a Categorical Scale | Moderately so | 33.7 Percentage of Participants |
| Placebo | Highest Rating of Desire/Urge to Smoke on a Categorical Scale | Not at all | 2.2 Percentage of Participants |
| Placebo | Highest Rating of Desire/Urge to Smoke on a Categorical Scale | Very much so | 22.8 Percentage of Participants |
| Placebo | Highest Rating of Desire/Urge to Smoke on a Categorical Scale | Extremely so | 10.9 Percentage of Participants |
| Placebo | Highest Rating of Desire/Urge to Smoke on a Categorical Scale | Somewhat | 30.4 Percentage of Participants |
| Nicotine | Highest Rating of Desire/Urge to Smoke on a Categorical Scale | Extremely so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Desire/Urge to Smoke on a Categorical Scale | Somewhat | 100 Percentage of Participants |
| Nicotine | Highest Rating of Desire/Urge to Smoke on a Categorical Scale | Moderately so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Desire/Urge to Smoke on a Categorical Scale | Very much so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Desire/Urge to Smoke on a Categorical Scale | Not at all | 0 Percentage of Participants |
Secondary
Highest Rating of Difficulty Concentrating on a Categorical Scale
Participants are asked if during the last 24 hours they experienced Difficulty Concentrating on a 5-grade categorical scale from Not at all to Extremely so.
Time frame: within 12 Weeks
Population: Analysis was limited to participants who used study medication at least once and completed the questionnaire.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Highest Rating of Difficulty Concentrating on a Categorical Scale | Moderately so | 15.2 Percentage of Participants |
| Placebo | Highest Rating of Difficulty Concentrating on a Categorical Scale | Somewhat | 18.5 Percentage of Participants |
| Placebo | Highest Rating of Difficulty Concentrating on a Categorical Scale | Very much so | 9.8 Percentage of Participants |
| Placebo | Highest Rating of Difficulty Concentrating on a Categorical Scale | Extremely so | 3.3 Percentage of Participants |
| Placebo | Highest Rating of Difficulty Concentrating on a Categorical Scale | Not at all | 53.3 Percentage of Participants |
| Nicotine | Highest Rating of Difficulty Concentrating on a Categorical Scale | Extremely so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Difficulty Concentrating on a Categorical Scale | Moderately so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Difficulty Concentrating on a Categorical Scale | Not at all | 50.0 Percentage of Participants |
| Nicotine | Highest Rating of Difficulty Concentrating on a Categorical Scale | Very much so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Difficulty Concentrating on a Categorical Scale | Somewhat | 50.0 Percentage of Participants |
Secondary
Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale
Participants are asked if during the last 24 hours they experienced Dysphoric or Depressed Mood on a 5-grade categorical scale from Not at all to Extremely so.
Time frame: within 12 Weeks
Population: Analysis was limited to participants who used study medication at least once and who completed the questionnaire.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale | Somewhat | 19.6 Percentage of Participants |
| Placebo | Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale | Very much so | 3.3 Percentage of Participants |
| Placebo | Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale | Moderately so | 9.8 Percentage of Participants |
| Placebo | Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale | Extremely so | 1.1 Percentage of Participants |
| Placebo | Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale | Not at all | 66.3 Percentage of Participants |
| Nicotine | Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale | Extremely so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale | Not at all | 0 Percentage of Participants |
| Nicotine | Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale | Somewhat | 100 Percentage of Participants |
| Nicotine | Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale | Moderately so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale | Very much so | 0 Percentage of Participants |
Secondary
Highest Rating of Increased Appetite on a Categorical Scale
Participants are asked if during the last 24 hours they experienced Increased Appetite on a 5-grade categorical scale from Not at all to Extremely so.
Time frame: within 12 Weeks
Population: Analysis was limited to participants who used study medication at least once and who completed the questionnaire.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Highest Rating of Increased Appetite on a Categorical Scale | Somewhat | 13.0 Percentage of Participants |
| Placebo | Highest Rating of Increased Appetite on a Categorical Scale | Very much so | 15.2 Percentage of Participants |
| Placebo | Highest Rating of Increased Appetite on a Categorical Scale | Moderately so | 15.2 Percentage of Participants |
| Placebo | Highest Rating of Increased Appetite on a Categorical Scale | Extremely so | 2.2 Percentage of Participants |
| Placebo | Highest Rating of Increased Appetite on a Categorical Scale | Not at all | 54.3 Percentage of Participants |
| Nicotine | Highest Rating of Increased Appetite on a Categorical Scale | Extremely so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Increased Appetite on a Categorical Scale | Not at all | 0 Percentage of Participants |
| Nicotine | Highest Rating of Increased Appetite on a Categorical Scale | Somewhat | 100 Percentage of Participants |
| Nicotine | Highest Rating of Increased Appetite on a Categorical Scale | Moderately so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Increased Appetite on a Categorical Scale | Very much so | 0 Percentage of Participants |
Secondary
Highest Rating of Insomnia on a Categorical Scale
Participants are asked if during the last 24 hours they experienced Insomnia on a 5-grade categorical scale from Not at all to Extremely so.
Time frame: within 12 Weeks
Population: Analysis was limited to participants who used study medication at least once and who completed the questionnaire.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Highest Rating of Insomnia on a Categorical Scale | Somewhat | 22.8 Percentage of Participants |
| Placebo | Highest Rating of Insomnia on a Categorical Scale | Moderately so | 10.9 Percentage of Participants |
| Placebo | Highest Rating of Insomnia on a Categorical Scale | Very much so | 3.3 Percentage of Participants |
| Placebo | Highest Rating of Insomnia on a Categorical Scale | Extremely so | 6.5 Percentage of Participants |
| Placebo | Highest Rating of Insomnia on a Categorical Scale | Not at all | 56.5 Percentage of Participants |
| Nicotine | Highest Rating of Insomnia on a Categorical Scale | Not at all | 50.0 Percentage of Participants |
| Nicotine | Highest Rating of Insomnia on a Categorical Scale | Extremely so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Insomnia on a Categorical Scale | Moderately so | 50.0 Percentage of Participants |
| Nicotine | Highest Rating of Insomnia on a Categorical Scale | Somewhat | 0 Percentage of Participants |
| Nicotine | Highest Rating of Insomnia on a Categorical Scale | Very much so | 0 Percentage of Participants |
Secondary
Highest Rating of Irritability/Frustration/Anger on a Categorical Scale
Participants are asked if during the last 24 hours they experienced Irritability/Frustration/Anger on a 5-grade categorical scale from Not at all to Extremely so.
Time frame: within 12 Weeks
Population: Analysis was limited to participants who used study medication at least once and who completed the questionnaire.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Highest Rating of Irritability/Frustration/Anger on a Categorical Scale | Extremely so | 3.3 Percentage of Participants |
| Placebo | Highest Rating of Irritability/Frustration/Anger on a Categorical Scale | Somewhat | 27.2 Percentage of Participants |
| Placebo | Highest Rating of Irritability/Frustration/Anger on a Categorical Scale | Not at all | 30.4 Percentage of Participants |
| Placebo | Highest Rating of Irritability/Frustration/Anger on a Categorical Scale | Moderately so | 23.9 Percentage of Participants |
| Placebo | Highest Rating of Irritability/Frustration/Anger on a Categorical Scale | Very much so | 15.2 Percentage of Participants |
| Nicotine | Highest Rating of Irritability/Frustration/Anger on a Categorical Scale | Very much so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Irritability/Frustration/Anger on a Categorical Scale | Moderately so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Irritability/Frustration/Anger on a Categorical Scale | Extremely so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Irritability/Frustration/Anger on a Categorical Scale | Not at all | 50.0 Percentage of Participants |
| Nicotine | Highest Rating of Irritability/Frustration/Anger on a Categorical Scale | Somewhat | 50.0 Percentage of Participants |
Secondary
Highest Rating of Restlessness on a Categorical Scale
Participants are asked if during the last 24 hours they experienced Restlessness on a 5-grade categorical scale from Not at all to Extremely so.
Time frame: within 12 Weeks
Population: Analysis was limited to participants who used study medication at least once and who completed the questionnaire.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Highest Rating of Restlessness on a Categorical Scale | Somewhat | 25.0 Percentage of Participants |
| Placebo | Highest Rating of Restlessness on a Categorical Scale | Very much so | 13.0 Percentage of Participants |
| Placebo | Highest Rating of Restlessness on a Categorical Scale | Moderately so | 12.0 Percentage of Participants |
| Placebo | Highest Rating of Restlessness on a Categorical Scale | Extremely so | 6.5 Percentage of Participants |
| Placebo | Highest Rating of Restlessness on a Categorical Scale | Not at all | 43.5 Percentage of Participants |
| Nicotine | Highest Rating of Restlessness on a Categorical Scale | Extremely so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Restlessness on a Categorical Scale | Not at all | 0 Percentage of Participants |
| Nicotine | Highest Rating of Restlessness on a Categorical Scale | Somewhat | 100 Percentage of Participants |
| Nicotine | Highest Rating of Restlessness on a Categorical Scale | Moderately so | 0 Percentage of Participants |
| Nicotine | Highest Rating of Restlessness on a Categorical Scale | Very much so | 0 Percentage of Participants |
Secondary
Mean Number of Daily Doses
Mean number of daily doses by study week.
Time frame: Week 6
Population: Analysis was limited to data collected from participants at Week 6. Analysis of data for the remainder of the study weeks was not possible because the trial terminated prematurely due to a technical issue (randomization error).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Mean Number of Daily Doses | 13.3 Daily Doses | Standard Deviation 12.8 |
Secondary
Mean Number of Daily Doses
Mean number of daily doses by study week.
Time frame: Week 5
Population: Analysis was limited to data collected from participants at Week 5.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Mean Number of Daily Doses | 10.9 Daily Doses | Standard Deviation 11.3 |
| Nicotine | Mean Number of Daily Doses | 4.0 Daily Doses | Standard Deviation 0 |
Secondary
Mean Number of Daily Doses
Mean number of daily doses by study week.
Time frame: Week 4
Population: Analysis was limited to data collected from participants at Week 4.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Mean Number of Daily Doses | 12.2 Daily Doses | Standard Deviation 10.8 |
| Nicotine | Mean Number of Daily Doses | 10.5 Daily Doses | Standard Deviation 5.7 |
Secondary
Mean Number of Daily Doses
Mean number of daily doses by study week.
Time frame: Week 3
Population: Analysis was limited to data collected from participants at Week 3.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Mean Number of Daily Doses | 13.1 Daily Doses | Standard Deviation 9.4 |
| Nicotine | Mean Number of Daily Doses | 15.8 Daily Doses | Standard Deviation 9.2 |
Secondary
Mean Number of Daily Doses
Mean number of daily doses by study week.
Time frame: Week 2
Population: Analysis was limited to data collected from participants at Week 2.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Mean Number of Daily Doses | 15.8 Daily Doses | Standard Deviation 11.4 |
| Nicotine | Mean Number of Daily Doses | 18.0 Daily Doses | Standard Deviation 14.2 |
Secondary
Mean Number of Daily Doses
Mean number of daily doses by study week.
Time frame: Week 1
Population: Analysis was limited to data collected from participants at Week 1.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Mean Number of Daily Doses | 16.7 Daily Doses | Standard Deviation 11.7 |
| Nicotine | Mean Number of Daily Doses | 14.9 Daily Doses | Standard Deviation 7.3 |
Secondary
Number of Participants With 7-day Point Prevalence Abstinence
Number of participants with carbon monoxide (CO)-verified self-reported 7-day point prevalence abstinence from smoking at Weeks 2, 4, 6, 12, 16, and 26.
Time frame: through Week 26
Population: The study was terminated prematurely due to a technical issue (randomization error).
Secondary
Number of Participants With Continuous Smoking Abstinence
Number of participants with carbon monoxide (CO)-verified self report of continuous abstinence from smoking from Week 2 to Weeks 4, 6, 12, 16, and 26.
Time frame: through Week 26
Population: The study was terminated prematurely due to a technical issue (randomization error) and no data are available.
Secondary
Participant Score for Change in Perception
Participants are asked to rate how their opinion has changed since the first time they used it, on a score of 1-5, where 1=I like it much less now and 5=I like it much more now.
Time frame: through 12 Weeks
Population: The study was terminated prematurely due to a technical issue (randomization error) and no data are available.
Secondary
Participant Score for General Perception of the Product
Participants are asked to rate their general perception of the investigational product on a scale of 1-10, where 1=very poor and 10=excellent.
Time frame: through Week 12
Population: The study was terminated prematurely due to a technical issue (randomization error) and no data are available.
Secondary
Participant Score for Product Convenience
Participants are asked to rate how convenient the product is to use, on a scale of 1-5, where 1=not at all convenient and 5=extremely convenient.
Time frame: through 12 Weeks
Population: The study was terminated prematurely due to a technical issue (randomization error) and no data are available.
Secondary
Participant Score for Product Effectiveness in Dealing With Cravings
Participants are asked to rate the product in its effectiveness for dealing with cravings, on a scale of 1-5, where 1=not at all effective, and 5=extremely effective.
Time frame: through 12 Weeks
Population: The study was terminated prematurely due to a technical issue (randomization error) and no data are available.
Secondary
Participant Score for Speed of Action
Participants are asked to rate the product for speed of action, on a scale of 1-9, where 1=extremely slow and 9=extremely fast.
Time frame: through 12 Weeks
Population: The study was terminated prematurely due to a technical issue (randomization error) and no data are available.
Secondary
Percentage of Participants With High Dosage
Percentage of participants who used more than 64 doses in any one-day period.
Time frame: within 12 Weeks
Population: Analysis was limited to data collected from participants who had used study medication at least one day.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With High Dosage | 2.0 Percentage of Participants |
| Nicotine | Percentage of Participants With High Dosage | 0 Percentage of Participants |
Secondary
Percentage of Participants With High Usage
Percentage of participants who used more than four doses in any one-hour period.
Time frame: within 12 Weeks
Population: Analysis was limited to data collected from participants who had used study medication at least one day.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With High Usage | 28.2 Percentage of Participants |
| Nicotine | Percentage of Participants With High Usage | 25 Percentage of Participants |